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Abstract Aims/hypothesis: The aim of this study was to
determine the impact of measurement of B-type natriuretic
peptide (BNP) levels on the management of patients with
diabetes presenting with acute dyspnoea. Methods: This
study evaluated the subgroup of 103 patients with diabetes
included in the B-type Natriuretic Peptide for Acute
Shortness of Breath Evaluation (BASEL) study (n=452).
Patients were randomly assigned to a diagnostic strategy
with (n=47, BNP group) or without (n=56, control group)
the use of BNP levels assessed by a rapid bedside assay.
Time to discharge and total cost of treatment were
recorded as the primary endpoints. Results: Although
similar with regard to age and sex, patients with diabetes
more often had pre-existing cardiovascular and renal
disease and heart failure as the cause of acute dyspnoea
compared with patients without diabetes. In addition,
medical and economic outcomes were worse in patients
with diabetes. The use of BNP levels significantly reduced
time to discharge (median 9 days [interquartile range
(IQR) 2–16] in the BNP group vs 13 days [IQR 8–22] in
the control group; p=0.016). At 30 days, the diabetic
patients in the BNP group had spent significantly fewer
days in hospital compared with the diabetic patients in
the control group (9 days [IQR 2–19] vs 16 days [IQR 8–
24], respectively; p=0.008). Total treatment costs at
30 days were US$5,705 (IQR 2,285–9,137) in the BNP
group and US$7,420 (IQR 4,194–11,966) in the control
group (p=0.036). Conclusions/interpretation: The results
of this study indicate that measurement of BNP levels
improves the management of patients with diabetes
presenting with acute dyspnoea.
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Introduction
The evaluation and management of patients presenting to
the emergency department (ED) with acute dyspnoea is
challenging. Among more than 30 diagnoses that may be
responsible for the acute dyspnoea, heart failure is very
common and therefore important [1–3]. Unfortunately, the
rapid and accurate differentiation of heart failure from other
causes of acute dyspnoea often remains elusive, particularly
in patients with diastolic heart failure. Misdiagnosis of heart
failure causes morbidity and increases time to discharge and
treatment costs, because treatments for heart failure may be
hazardous to patients with other conditions such as chronic
obstructive lung disease (COPD), and vice versa [4–6].
Patients with diabetes have an increased risk of developing
heart failure and are particularly affected by the diagnostic
dilemma surrounding heart failure. The incidence of heart
failure is two-fold higher in diabetic vs non-diabetic men
and five-fold higher in diabetic vs non-diabetic women [7].
Patients with diabetic cardiomyopathy display clinical and
anatomical features of heart failure that are different from
those displayed by other heart failure patients [8]. Diabetic
cardiomyopathy is a distinct entity characterised by left
ventricular diastolic dysfunction caused by myocardial
fibrosis and hypertrophy, which occur in response to
hyperglycaemia and insulin resistance [9–11]. Using sensi-
tive echocardiographic techniques, diastolic dysfunction can
be detected in 50–60% of asymptomatic patients with
diabetes [12, 13].
B-type natriuretic peptide (BNP) is a novel cardiac
marker that is reliably elevated in the setting of heart failure,
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and may therefore be very helpful in its diagnosis [14–16].
Observational studies have shown that the use of BNP levels
significantly increases the accuracy of the clinical diagnosis
in patients presenting with acute dyspnoea to the ED [14–
16]. However, BNP levels are significantly lower in patients
with left ventricular diastolic dysfunction—the predominant
mechanism of heart failure in patients with diabetes—than
in patients with left ventricular systolic dysfunction [15, 16].
In addition, diabetes is associated with kidney disease. This
is considered a limitation for the diagnostic use of BNP, as
kidney disease results in elevated BNP levels independently
of heart failure [17, 18].
These differences and our previous findings in patients
with diabetes [19, 20] have fostered the need to specifically
evaluate whether the promising results obtained for BNP
testing for acute dyspnoea in unselected patient cohorts
[21, 22] can be extrapolated to patients with diabetes. This
study sought to evaluate the impact of a BNP-guided
diagnostic strategy on the evaluation and management of
diabetic patients presenting with acute dyspnoea to the ED.
Subjects and methods
Setting and study population This study specifically
evaluated the outcome of patients with diabetes in the B-
type Natriuretic Peptide for Acute Shortness of Breath
Evaluation (BASEL) study [22]. The BASEL study was a
prospective, randomised, single-blind study conducted in
the ED of the University Hospital in Basel, Switzerland,
from May 2001 to April 2002. The study was carried out
in accordance with the Declaration of Helsinki and was
approved by the local ethics committee. Written informed
consent was obtained from all participating patients.
To be eligible for the study, a patient had to present with
shortness of breath as the primary complaint and no
obvious traumatic cause of dyspnoea. Patients with severe
renal disease (serum creatinine >250 μmol/l), patients in
cardiogenic shock, and patients who requested an early
transfer to another hospital were excluded. A total of 452
patients were enrolled in the BASEL study and randomly
assigned according to a computer-generated randomisation
scheme 1:1 without stratification to receive a diagnostic
strategy with (n=225, including 47 patients with diabetes
[BNP group]) or without (n=227, including 56 patients
with diabetes [control group]) the use of BNP levels
determined by a rapid bedside assay. Diabetes was defined
as a known history of diabetes treated currently with diet,
oral glucose-lowering agents or insulin.
Routine clinical assessment Patients underwent an initial
clinical assessment that included clinical history, physical
examination, ECG, pulse oximetry, blood tests (including
arterial blood gas analysis when indicated) and chest X-
ray. Echocardiography and pulmonary function tests were
strongly recommended in the ED on an outpatient basis or
in the hospital if the patient was admitted.
Measurement and interpretation of BNP levels During
initial evaluation, at the time of venipuncture for routine
blood tests, a venous specimen of blood (3 ml) was
collected into tubes containing potassium EDTA. BNP
was measured using a rapid fluorescence immunoassay
(Biosite Diagnostics, La Jolla, CA, USA). The precision,
analytical sensitivity and stability characteristics of the
system have been described previously [23]. In brief, the
CVs for intra-assay precision have been reported to be
9.5, 12.0 and 13.9%, and the CVs for interassay precision
are known to be 10.0%, 12.4 and 14.8% for BNP levels
of 28.8, 584.0 and 1180.0 pg/ml, respectively [23]. The
analytical sensitivity was <5.0 pg/ml, with a measurable
range of 1–1,300 pg/ml.
In the BNP-guided group, diagnostic and therapeutic
decisions were not based on BNP levels alone; rather, the
information provided by the BNP level was integrated
with the clinical results, as described previously [22]. In
brief, we used two BNP cut-off levels (100 and 500 pg/ml)
to differentiate heart failure from other causes of dys-
pnoea. In patients with a BNP level below 100 pg/ml,
heart failure was considered unlikely and alternative
causes of dyspnoea had to be pursued. In patients with a
BNP level above 500 pg/ml, heart failure was considered
likely and rapid therapy with diuretics, nitroglycerin, ACE
inhibitors and morphine was recommended. For patients
with BNP levels between 100 and 500 pg/ml, the protocol
recommended clinical judgement and possible further
diagnostic testing. Patients in the control group were
evaluated and managed according to the most recent
clinical practice guidelines [1–3].
Endpoints Time to discharge and cost of treatment were
defined as the primary endpoints of this study. Time to
discharge was defined as the time interval from presen-
tation to the ED to hospital discharge. As cost:charge
ratios have not been defined for the majority of services
and departments at our institution, hospital charges were
collected as the most appropriate estimate of true costs
[24, 25]. To avoid imbalance introduced by varying
hospital contracts with different insurances or different
insurance classes, charges were standardised to the actual
rates for patients with general insurance, living in Basel.
For the measurement of BNP, the current reimbursement
in Switzerland (US$47) was used. Endpoints were
assessed by physicians not involved in patient care and
blinded to the assigned group using all medical records
pertaining to the patient.
Statistical analyses The statistical analyses were per-
formed using the SPSS/PC software package (version
12.0; SPSS, Chicago, IL, USA). A statistical significance
level of 0.05 was used. All data were analysed on an
intention-to-treat basis. Comparisons were made using the
t test for normally distributed continuous variables, the
Mann–Whitney U test for non-normally distributed con-
tinuous variables, Fisher’s exact test for categorical
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variables with any field including fewer than six patients,
and the χ2 test for the other categorical variables. All
hypothesis testing was two-tailed.
Results
A total of 103 patients with diabetes were enrolled in this
trial (Fig. 1). Although these patients were similar to the
non-diabetic patients in terms of age and sex, diabetic
patients more often had pre-existing cardiovascular and
renal disease (Table 1). As regards symptoms, chest pain
and nycturia were more frequent in diabetic subjects.
Assessment of clinical signs revealed that rales and lower-
extremity oedema were more frequent in diabetic patients.
In addition, patients with diabetes had significantly lower
haemoglobin and albumin, but higher serum creatinine and
BNP compared with patients without diabetes.
The final discharge diagnosis was significantly different
in patients with diabetes compared with patients without
diabetes. Heart failure was more often the cause of acute
dyspnoea in patients with diabetes (65 vs 43%), whereas
obstructive pulmonary disease and anxiety disorder were
less often the cause in these patients. Interestingly, medical
and economic outcomes were different—to the detriment
of patients with diabetes. BNP was similar in heart failure
patients with or without diabetes (median 812 vs 795 pg/ml,
p=0.236). BNP was also similar in patients without heart
failure with or without diabetes (median 135 vs 57 pg/ml,
p=0.134). Diabetic patients more often required hospitalisa-
tion and recovered more slowly, resulting in an increased
time to discharge and an increase in the number of days in
hospital at 30 days after initial presentation. Moreover,
initial and 30-day total treatment costs were significantly
higher in patients with diabetes.
The two groups of diabetic patients were well matched in
terms of baseline characteristics (Table 2). The use of BNP
levels significantly affected patient management. Patients
assigned to the BNP group required hospitalisation less
often. As shown in Fig. 2, the use of BNP levels
significantly reduced time to discharge (median 9 days
[interquartile range (IQR) 2–16] in the BNP group vs
13 days [IQR 8–22] in the control group; p=0.016). At
30 days, diabetic patients in the BNP group had spent
significantly fewer days in hospital than the those in the
control group (9 days [IQR 2–19] vs 16 days [IQR 8–24];
p=0.008). In-hospital and 30-day mortality were lower in
the BNP group. However, the between-group differences
were not statistically significant. Interestingly, this medical
benefit was accompanied by an economic benefit, with a
relative reduction in initial and 30-day treatment costs in
the BNP group. Total treatment costs at 30 days were US
$5,705 (IQR 2,285–9,137) in the BNP group and US
$7,420 (IQR 4,194–11,966) in the control group (p=0.036).
Similar benefits of BNP testing were observed in non-
diabetic patients. The use of BNP levels significantly
reduced time to discharge (median 7 days [IQR 1–16] in
the BNP group vs 10 days [IQR 3–18] in the control
group; p=0.027) and total treatment costs at 30 days (US
$3,841 [IQR 601–7,545] in the BNP group vs US$5,432
(IQR 2,572–9,930) in these subjects (p=0.014).
Discussion
In this study we examined the use of BNP levels in the
management of diabetic patients presenting with acute
dyspnoea to the ED. We report four major findings. First,
patients with diabetes represent a high-risk group with
increased cardiovascular and renal comorbidity. However,
Fig. 1 Patient flow through trial
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Table 1 Baseline characteristics in patients with and without diabetes mellitus
Diabetes n=103 No diabetes n=349 p value
Age (years) 72±10 70±16 0.157
Sex 0.153
Male 66 (64) 196 (56)
Female 37 (36) 153 (44)
History
Coronary artery disease 71 (69) 154 (44) <0.001
Arterial hypertension 79 (77) 158 (45) <0.001
COPD 33 (32) 107 (31) 0.790
Asthma 4 (4) 25 (7) 0.358
Pneumonia 15 (15) 43 (12) 0.550
Pulmonary embolism 12 (12) 19 (5) 0.029
Other pulmonary or pleural disease 15 (15) 31 (9) 0.094
Any pulmonary disease 57 (55) 169 (48) 0.217
Depressive disorder 9 (9) 27 (8) 0.741
Stroke or peripheral vascular disease 31 (30) 58 (17) 0.003
Chronic kidney disease 35 (34) 77 (22) 0.014
Deep vein thrombosis 10 (10) 31 (9) 0.798
Symptoms
Shortness of breatha 0.474
Slight hill 14 (14) 51 (15)
Level ground 55 (53) 202 (58)
At rest 32 (31) 94 (27)
Paroxysmal nocturnal dyspnoea 45 (44) 121 (35) 0.095
Nycturia 45 (44) 91 (26) 0.001
Weight gain 17 (17) 34 (10) 0.057
Chest pain 45 (44) 109 (31) 0.019
Coughing 46 (45) 178 (51) 0.258
Expectoration 34 (33) 125 (36) 0.600
Fever 22 (21) 87 (25) 0.457
Vital status
Systolic blood pressure (mmHg) 153±27 143±28 0.003
Diastolic blood pressure (mmHg) 87±18 85±19 0.520
Heart rate (per min) 97±21 98±25 0.717
Temperature (oC) 37.4±1.0 37.4±1.0 0.735
Signs
Tachypnoea (>20 per min) 52 (51) 158 (45) 0.351
Elevated jugular venous pressure 18 (18) 46 (13) 0.272
Hepatojugular reflux 7 (7) 42 (12) 0.133
Rales 61 (59) 146 (42) 0.002
Wheezing 22 (21) 78 (22) 0.832
Hyper-resonant percussion 8 (8) 31 (9) 0.723
Dullness 14 (14) 32 (9) 0.192
Lower-extremity oedema 48 (47) 108 (31) 0.003
Laboratory tests
Haemoglobin (g/l) 128±24 137±27 0.005
Serum creatinine (μmol/l) 132±62 109±54 <0.001
Serum albumin (g/l) 32±5 34±5 0.009
Troponin I (μg/l) 6.1±16.9 6.1±35.3 0.997
B-Type natriuretic peptide (pg/ml)b 372 [144–961] 202 [35–770] 0.060
Final discharge diagnosis
Congestive heart failure 67 (65) 150 (43) <0.001
Left ventricular ejection fraction (%)c 40 [30–55] 40 [30–55] 0.761
Obstructive pulmonary disease 10 (10) 66 (19) 0.028
Pulmonary embolism 2 (2) 19 (5) 0.185
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it is important to note that 30-day mortality was similar for
diabetic and non-diabetic patients. Second, heart failure is
the predominant cause of acute dyspnoea in patients with
diabetes. Third, patients with diabetes had worse medical
and economic outcomes compared with patients without
diabetes. Fourth, used in conjunction with other clinical
information, rapid measurement of BNP in the ED
improves the management of diabetic patients presenting
with acute dyspnoea, and thereby reduces the time to
discharge, days in hospital at 30 days, and the total
treatment cost. Given the predominance of left ventricular
diastolic dysfunction, the distinct features of diabetic
cardiomyopathy, and the high prevalence of kidney disease
in patients with diabetes, this finding supports the clinical
use of BNP in patients with diabetes [7–13]. Given both the
significant morbidity associated with acute dyspnoea and
the considerable cost associated with heart failure and other
causative disorders [1–6], BNP testing seems to represent a
major advance in the evaluation and management of
diabetic patients who present with acute dyspnoea.
Additional studies are necessary to further evaluate
whether this improvement in patient management also
reduces mortality.
The findings of the BASEL study build on the con-
clusions of observational studies in which BNP levels were
validated by comparison with a retrospectively adjudicated
‘gold standard’ for the diagnosis of heart failure by two
independent cardiologists [14–17]. In the Breathing Not
Properly Multinational Study, BNP levels alone were more
accurate than any historical or physical finding or labora-
tory value in identifying heart failure as the cause of acute
dyspnoea. The diagnostic accuracy of BNP at a cut-off
value of 100 pg/ml was 83%, with a sensitivity of 90% and
a specificity of 76% [14, 17]. Our data show that a rapid
and more accurate diagnosis avoids unnecessary hospital-
isation, reduces the time to the initiation of the adequate
therapy and reduces time to discharge, irrespective of the
presence or absence of diabetes [26–30]. Recent subgroup
analysis from the Breathing Not Properly Multinational
Study suggested that a history of diabetes does not affect
the accuracy of BNP levels in the detection of heart failure
as the cause of acute dyspnoea [29]. There was no
significant difference in median BNP levels between
diabetes and no diabetes among patients without heart
failure (32 vs 33 pg/ml), patients with heart failure (587 vs
494 pg/ml), and those with a history of heart failure (180 vs
120 pg/ml). In this study we were able to confirm this
finding. Moreover, in contrast to kidney disease, the
presence of diabetes does not seem to necessitate a change
in cut-off values [17, 29]. Our data confirm and extend this
finding by showing that the use of BNP as an accurate
marker of heart failure without cut-off value adjustment for
the presence of diabetes significantly improves medical and
economic outcomes in diabetic patients presenting with
acute dyspnoea to the ED. As heart failure is the cause of
dyspnoea in two-thirds of diabetic patients with acute
dyspnoea, the use of an accurate heart failure marker could
have a considerable impact. Moreover, as diabetic patients
with acute dyspnoea have higher rates of hospitalisation
and longer in-hospital stays, this high-risk cohort has much
to gain from the use of BNP level.
In normotensive non-insulin-dependent diabetic patients
with microalbuminuria, a significant positive correlation
between plasma BNP levels and urinary albumin excretion
rate (r=0.58) was found [26]. Moreover, BNP testing may
be helpful as a screen for left ventricular dysfunction in
patients with diabetes. Epshteyn and colleagues screened
diabetic patients with and without a clinical indication for
echocardiography [27]. Irrespective of the clinical indica-
tion for echocardiography, BNP levels were significantly
Diabetes n=103 No diabetes n=349 p value
Pneumonia 14 (14) 48 (14) 0.967
Anxiety disorder 0 16 (5) 0.029
Other diseased 11 (11) 48 (14) 0.416
Unknown cause 6 (6) 14 (4) 0.432
Outcome
Time to treatment (min) 62 [16–159] 73 [20–180] 0.160
Hospital admission 91 (88) 271 (78) 0.017
Time to discharge (days) 12 [5–19] 9 [1–17] 0.020
Initial treatment cost (US$) 5,740 [2,924–9,056] 4,457 [887–7,881] 0.018
In-hospital mortality 6 (6) 28 (8) 0.457
30-day in-hospital days 13 [6–22] 9 [2–18] 0.002
30-day treatment cost (US$) 6,110 [3,518–10,238] 4,827 [1,199–8,023] 0.001
30-day mortality 8 (8) 42 (12) 0.225
Data are presented as mean±SD, median [IQR] or number of patients (%)
aTwo patients in each group had dyspnoea only when climbing a steep incline
bIn the BNP group, n=225
cAvailable in 148 patients
dIncluding interstitial lung disease, pleural effusion, anaemia and sepsis
Table 1 (continued)
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Table 2 Baseline characteristics in patients with diabetes assigned to the control and the BNP groups
Control group n=56 BNP group n=47 p value
Age (years) 72±10 73±11 0.777
Sex 0.962
Male 36 (64) 30 (64)
Female 20 (36) 17 (36)
History
Coronary artery disease 36 (64) 35 (75) 0.266
Arterial hypertension 43 (77) 36 (77) 0.982
COPD 17 (30) 16 (34) 0.690
Asthma 2 (4) 2 (4) 1.000
Pneumonia 9 (16) 6 (13) 0.636
Pulmonary embolism 6 (11) 6 (13) 0.746
Other pulmonary or pleural disease 9 (16) 6 (13) 0.636
Any pulmonary disease 31 (55) 26 (55) 0.997
Depressive disorder 7 (13) 2 (4) 0.176
Stroke or peripheral vascular disease 18 (32) 13 (28) 0.621
Chronic kidney disease 18 (32) 17 (36) 0.667
Deep vein thrombosis 5 (9) 5 (11) 1.000
Symptoms
Shortness of breatha 0.780
Slight hill 6 (11) 8 (17)
Level ground 30 (54) 25 (53)
At rest 19 (34) 13 (28)
Paroxysmal nocturnal dyspnoea 26 (46) 19 (40) 0.541
Weight gain 9 (16) 8 (17) 0.897
Nycturia 27 (48) 18 (38) 0.312
Chest pain 25 (45) 20 (43) 0.831
Coughing 30 (54) 16 (34) 0.047
Expectoration 22 (39) 12 (26) 0.139
Fever 11 (20) 11 (23) 0.643
Vital status
Systolic blood pressure (mmHg) 149±27 157±28 0.109
Diastolic blood pressure (mmHg) 88±19 85±17 0.502
Heart rate (per min) 99±24 94±17 0.266
Temperature (oC) 37.4±0.9 37.3±1.1 0.735
Signs
Tachypnoea (>20 per min) 30 (54) 22 (47) 0.494
Elevated jugular venous pressure 11 (20) 7 (15) 0.527
Hepatojugular reflux 2 (4) 5 (11) 0.241
Rales 32 (57) 29 (62) 0.639
Wheezing 10 (18) 12 (26) 0.344
Hyper-resonant percussion 5 (9) 3 (6) 0.724
Dullness 10 (18) 4 (9) 0.249
Lower-extremity oedema 28 (50) 20 (43) 0.450
Laboratory tests
Haemoglobin (g/l) 127±24 130±24 0.578
Serum creatinine (μmol/l) 136±70 128±51 0.523
Serum albumin (g/l) 32±5 33±5 0.395
Troponin I (μg/l) 6.4±17.3 5.8±16.7 0.892
Endpoints
Time to treatment (min) 71 (17–207) 61 (13–133) 0.151
Time to discharge (days) 13 (8–22) 9 (2–16) 0.016
Hospital admission 53 (95) 38 (81) 0.036
Initial treatment cost (US$) 5,940 (3,641–10,731) 5,538 (1,200–8,673) 0.093
In-hospital mortality 4 (7) 2 (4) 0.686
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higher in patients with left ventricular dysfunction. The
receiver operating characteristic curve revealed that the
AUC was 0.91 for patients with a clinical indication for
echocardiography and 0.81 for those without. For the latter
group, a BNP level below 39 pg/ml had a negative
predictive value of 91%.
The diabetic population in this study was highly
representative of the elderly diabetic population currently
presenting to the ED in the USA and Europe [1–4, 14, 19].
Comorbidity is extensive in this population and includes
coronary artery disease in more than two-thirds of these
patients, arterial hypertension in nearly 80%, and pulmo-
nary disease in more than 50%. The rapid and accurate
differentiation of heart failure from pulmonary causes of
dyspnoea in the ED in these patients is often difficult, but is
essential for cost-effective management.
Several limitations apply to this study. First, our inter-
pretation of the BNP test results was based on the data
available when the study protocol was devised. Subsequent
studies have shown that the use of the two cut-off values
(100 and 500 pg/ml) in the BASEL study is also appropriate
in patients with diabetes, as BNP cut-off values need not be
corrected for age, sex or diabetes [14, 29]. However, recent
subgroup analyses from the Breathing Not Properly Multi-
national Study suggest that the use of a higher first cut-off
value (200–225 pg/ml rather than 100 pg/ml, to exclude
heart failure) seems to provide higher accuracy in patients
with renal disease [17]. In contrast, a lower first cut-off
value should be applied in obese patients [30]. Second,
randomisation was not stratified for diabetes. Therefore, it is
reassuring to note that the baseline characteristics of the
diabetic patients in the two groups were well matched.
In conclusion, our results confirm the findings of
observational studies and support the use of BNP testing
in the assessment of diabetic patients presenting with acute
dyspnoea. Used in conjunction with other clinical informa-
tion, rapid measurement of BNP improved the evaluation
and management of patients in the ED and thereby reduced
time to discharge and total cost of treatment.
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